Total Refinement Solutions LLC Transitions to Royal Biotek Under $BLEG Portfolio

Royal Biotek: Pioneering Biotechnology Solutions for a Thriving Future

Melbourne, FL -- October 5, 2023 -- InvestorsHub NewsWire -- Total Refinement Solutions LLC, a pioneering company in the field of pharmaceutical biotechnology and a subsidiary of Branded Legacy, Inc (OTC.PK: BLEG), is excited to announce its transition to operate under the "Doing Business As" (DBA) name, Royal Biotek. This strategic rebranding represents a significant milestone in the company's evolution and reflects its commitment to innovation, excellence, and global recognition within the biotechnology sector.

With years of dedicated expertise in the development of cutting-edge biopharmaceutical solutions, Total Refinement Solutions LLC has earned a reputation for its unwavering commitment to scientific advancement, quality, and customer satisfaction. This transition to Royal Biotek is designed to enhance our visibility and better align our brand with our mission to create a healthier and more sustainable future through biotechnology innovation.

"The transition to Royal Biotek marks an exciting new chapter in our journey," said Dave Oswald, CEO of Branded Legacy. "Our commitment to traditional ecological knowledge, new research, and providing innovative solutions to the pharmaceutical industry remains unwavering. We believe that our new name will not only strengthen our brand but also amplify our impact on global healthcare."

Customers, partners, and stakeholders can rest assured that this rebranding will not affect the company's day-to-day operations or its dedication to providing exceptional products and services. The same team of experts, with their deep industry knowledge, will continue to drive the company forward under the Royal Biotek banner.

Royal Biotek will continue to focus on:

Advancing pharmaceutical biotechnology research via Traditional Ecological Knowledge, (TEK)
Developing innovative solutions to address global healthcare challenges.
Maintaining the highest standards of quality and integrity.
Strengthening partnerships with organizations and institutions worldwide.

The transition to the Royal Biotek name will be implemented immediately, and all future business activities will be conducted under this name. The company's official website and communication channels will be updated accordingly.

For more information about Royal Biotek and its innovative pharmaceutical biotechnology solutions, please visit our website at https://royalbiotek.com.

About Royal Biotek:

Royal Biotek, formerly known as Total Refinement Solutions LLC, and a subsidiary of Branded Legacy, Inc., is a leading company in the field of pharmaceutical biotechnology. With a commitment to excellence and innovation, Royal Biotek is dedicated to developing cutting-edge solutions that contribute to a healthier and more sustainable future.

About Branded Legacy Inc.

Branded Legacy Inc. is a forward-thinking biotechnology company dedicated to driving innovation in plant-derived medicines and biotechnological breakthroughs. The company's strategic partnerships and milestone achievements highlight its commitment to transforming patient care and contributing to the advancement of healthcare solutions. More Information on the Website: https://brandedlegacy.com/

Media Contact

Joe Holladay

Branded Legacy

Phone: 321-345-3565

Email: info@brandedlegacy.com

Website: https://brandedlegacy.com/

Safe Harbor Statement on Forward-Looking Language:

This release includes forward-looking statements, which are based on certain assumptions and reflect management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include general global economic conditions; general industry and market conditions and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, includes codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. Dilution, if any, would be for the purposes of management taking stock in lieu of cash salary. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Additionally, this press release that is not statements of historical fact may be considered to be forward-looking statements. Written words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the near future.